Yes, by the numbers.

Oral estrogen, with or without a progestogen, reduces weekly hot flush frequency by about 75 percent relative to placebo, which is why guideline bodies call hormone therapy the most effective vasomotor symptom treatment and recommend offering it to appropriate candidates within about 10 years of their final period. Newer nonhormonal drugs and other options can meaningfully help, especially when hormones are not suitable, but none has matched that margin in a direct comparison, and hormone therapy is not recommended for preventing heart disease or dementia even though it remains the strongest option for the flashes themselves.

What to know about this answer

There is no real dispute that hormone therapy has the largest effect size for the symptom itself. The genuine question for an individual woman is whether she is an appropriate candidate, and if not, which nonhormonal option fits her best.

What the research shows, and which source each finding rests on

Oral estrogen, with or without a progestogen, reduces weekly hot flush frequency by about 75 percent relative to placebo (weighted mean difference about -18 flushes/week; severity odds ratio 0.13)

A[1]

The Menopause Society's 2023 nonhormone statement states hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered in menopausal women within 10 years of their final menstrual period

A[2]

NICE NG23, updated November 2024, recommends offering hormone therapy for vasomotor symptoms, while stating it should not be used for prevention of cardiovascular disease or dementia

A[3]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Most effective is not the same as right for everyone

The guideline bodies' own framing, scoping the recommendation to appropriate candidates within a defined window

The same guidelines that call hormone therapy most effective also explicitly scope that recommendation to appropriate candidates within about 10 years of the final period, and separately state it should not be used to prevent cardiovascular disease or dementia, meaning the strongest treatment for the symptom is deliberately not framed as the strongest choice for every goal.

A[2]A[3]

What would settle it: This is already the guideline-settled answer for effect size on the symptom itself; what remains individualized is candidacy, which depends on a woman's own health history, risk factors, and preferences.

What is really going on here

  1. Is the percent reduction from baseline, or versus placebo? Hormone therapy's roughly 75 percent figure is already placebo-adjusted, and it helps to understand what that means when comparing it to other treatment claims.

Questions for your doctor

  1. Am I an appropriate candidate for hormone therapy based on my age, time since my final period, and health history?
  2. What form and dose would fit me best, oral or transdermal, with or without progestogen?
  3. If hormone therapy isn't right for me, what is the next most effective option?
  4. How will we monitor safety and reassess over time?

Questions with no answer yet

Would a trial redone today, using the same rigor as the newer nonhormonal drug trials, still find hormone therapy's roughly 75 percent reduction, or might that number look different measured against a modern placebo-controlled design?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The estrogen efficacy figure comes from a 2004 meta-analysis. More recent nonhormonal drug trials use different enrollment criteria and updated statistical methods, and there is no modern re-derivation of hormone therapy's effect size under comparable modern trial conditions.

What would test it: A modern, adequately powered placebo-controlled trial of standard-dose hormone therapy using the same design standards as the newer drug trials, to allow direct comparison.

For women within the ten-year appropriate-candidate window but at the very edge of it, does effectiveness for hot flashes decline gradually as time since menopause increases, or does it stay essentially flat until some tipping point?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Guideline bodies scope the hormone therapy recommendation to within about 10 years of the final menstrual period without specifying how the drug's effectiveness for the symptom itself, not risk, changes across that window.

What would test it: A study specifically modeling hot flash treatment effect size against time since final menstrual period, across the full candidacy window.

Since hormone therapy is not recommended for preventing heart disease or dementia even though it remains the strongest treatment for the symptom itself, could very effective symptom relief still carry indirect downstream health benefits, through better sleep and less stress, that current trials are not designed to detect?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Guidelines separate symptom treatment from disease prevention explicitly, and no trial in this evidence base tests whether the indirect pathway of symptom relief improving sleep and stress produces a measurable downstream benefit.

What would test it: A long-term trial or cohort study measuring whether the degree of symptom relief itself predicts downstream cardiovascular or cognitive outcomes, independent of the biological hormone exposure.

Sources

  1. 1.Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.MacLennan AH et al., Cochrane Database Syst Rev 2004 · Systematic review or guideline
  2. 2.The 2023 nonhormone therapy position statement of The North American Menopause Society.The North American Menopause Society 2023 nonhormone therapy position statement, Menopause 2023 · Systematic review or guideline
  3. 3.NICE guideline NG23, updated 7 November 2024Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides